Share this video  

EADO 2020 | Real-world use of t-vec in unresectable stage IIIB-IvM1a melanoma

Alexander van Akkooi, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, discusses a retrospective study that investigated the clinical use of talimogene laherparepvec (t-vec) in patients with unresectable stage IIIB-IvM1a melanoma in four European countries. This is interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter